A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis
Background. Retrospective, observational studies link high phosphate with mortality in dialysis patients. This generates research hypotheses but does not establish “cause-and-effect.” A large randomised controlled trial (RCT) of about 3000 patients randomised 50 : 50 to lower or higher phosphate ran...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2015/579434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563730709217280 |
|---|---|
| author | Ramya Bhargava Philip A. Kalra Paul Brenchley Helen Hurst Alastair Hutchison |
| author_facet | Ramya Bhargava Philip A. Kalra Paul Brenchley Helen Hurst Alastair Hutchison |
| author_sort | Ramya Bhargava |
| collection | DOAJ |
| description | Background. Retrospective, observational studies link high phosphate with mortality in dialysis patients. This generates research hypotheses but does not establish “cause-and-effect.” A large randomised controlled trial (RCT) of about 3000 patients randomised 50 : 50 to lower or higher phosphate ranges is required to answer the key question: does reducing phosphate levels improve clinical outcomes? Whether such a trial is technically possible is unknown; therefore, a study is necessary to inform the design and conduct of a future, definitive trial. Methodology. Dual centre prospective parallel group study: 100 dialysis patients randomized to lower (phosphate target 0.8 to 1.4 mmol/L) or higher range group (1.8 to 2.4 mmol/L). Non-calcium-containing phosphate binders and questionnaires will be used to achieve target phosphate. Primary endpoint: percentage successfully titrated to required range and percentage maintained in these groups over the maintenance period. Secondary endpoints: consent rate, drop-out rates, and cardiovascular events. Discussion. This study will inform design of a large definitive trial of the effect of phosphate on mortality and cardiovascular events in dialysis patients. If phosphate lowering improves outcomes, we would be reassured of the validity of this clinical practice. If, on the other hand, there is no improvement, a reassessment of resource allocation to therapies proven to improve outcomes will result. Trial Registration Number. This trial is registered with ISRCTN registration number ISRCTN24741445. |
| format | Article |
| id | doaj-art-c45d1a501952409cbf464c8c6b4203d3 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-c45d1a501952409cbf464c8c6b4203d32025-02-03T01:12:49ZengWileyInternational Journal of Nephrology2090-214X2090-21582015-01-01201510.1155/2015/579434579434A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on DialysisRamya Bhargava0Philip A. Kalra1Paul Brenchley2Helen Hurst3Alastair Hutchison4Institute of Cardio-Vascular Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PL, UKSalford Royal Hospitals NHS Foundation Trust, Salford M6 8HD, UKInstitute of Cardio-Vascular Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PL, UKManchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UKInstitute of Cardio-Vascular Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PL, UKBackground. Retrospective, observational studies link high phosphate with mortality in dialysis patients. This generates research hypotheses but does not establish “cause-and-effect.” A large randomised controlled trial (RCT) of about 3000 patients randomised 50 : 50 to lower or higher phosphate ranges is required to answer the key question: does reducing phosphate levels improve clinical outcomes? Whether such a trial is technically possible is unknown; therefore, a study is necessary to inform the design and conduct of a future, definitive trial. Methodology. Dual centre prospective parallel group study: 100 dialysis patients randomized to lower (phosphate target 0.8 to 1.4 mmol/L) or higher range group (1.8 to 2.4 mmol/L). Non-calcium-containing phosphate binders and questionnaires will be used to achieve target phosphate. Primary endpoint: percentage successfully titrated to required range and percentage maintained in these groups over the maintenance period. Secondary endpoints: consent rate, drop-out rates, and cardiovascular events. Discussion. This study will inform design of a large definitive trial of the effect of phosphate on mortality and cardiovascular events in dialysis patients. If phosphate lowering improves outcomes, we would be reassured of the validity of this clinical practice. If, on the other hand, there is no improvement, a reassessment of resource allocation to therapies proven to improve outcomes will result. Trial Registration Number. This trial is registered with ISRCTN registration number ISRCTN24741445.http://dx.doi.org/10.1155/2015/579434 |
| spellingShingle | Ramya Bhargava Philip A. Kalra Paul Brenchley Helen Hurst Alastair Hutchison A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis International Journal of Nephrology |
| title | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis |
| title_full | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis |
| title_fullStr | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis |
| title_full_unstemmed | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis |
| title_short | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis |
| title_sort | study to inform the design of a national multicentre randomised controlled trial to evaluate if reducing serum phosphate to normal levels improves clinical outcomes including mortality cardiovascular events bone pain or fracture in patients on dialysis |
| url | http://dx.doi.org/10.1155/2015/579434 |
| work_keys_str_mv | AT ramyabhargava astudytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT philipakalra astudytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT paulbrenchley astudytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT helenhurst astudytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT alastairhutchison astudytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT ramyabhargava studytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT philipakalra studytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT paulbrenchley studytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT helenhurst studytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis AT alastairhutchison studytoinformthedesignofanationalmulticentrerandomisedcontrolledtrialtoevaluateifreducingserumphosphatetonormallevelsimprovesclinicaloutcomesincludingmortalitycardiovasculareventsbonepainorfractureinpatientsondialysis |